Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes me… Read more
Galmed Pharmaceuticals Ltd - Asset Resilience Ratio
Galmed Pharmaceuticals Ltd (GLMD) has an Asset Resilience Ratio of 72.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Galmed Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Galmed Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.74 Million | 72.91% |
| Total Liquid Assets | $15.74 Million | 72.91% |
Asset Resilience Insights
- Very High Liquidity: Galmed Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 72.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Galmed Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Galmed Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Galmed Pharmaceuticals Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Galmed Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 57.72% | $10.68 Million | $18.50 Million | -1.09pp |
| 2023-12-31 | 58.82% | $9.78 Million | $16.63 Million | -12.25pp |
| 2022-12-31 | 71.06% | $11.77 Million | $16.56 Million | -16.17pp |
| 2021-12-31 | 87.23% | $31.93 Million | $36.60 Million | +3.35pp |
| 2020-12-31 | 83.88% | $43.94 Million | $52.38 Million | +6.67pp |
| 2019-12-31 | 77.21% | $59.56 Million | $77.14 Million | +4.33pp |
| 2018-12-31 | 72.88% | $66.03 Million | $90.60 Million | +42.46pp |
| 2017-12-31 | 30.42% | $5.98 Million | $19.64 Million | -44.66pp |
| 2016-12-31 | 75.08% | $12.35 Million | $16.45 Million | -2.59pp |
| 2015-12-31 | 77.67% | $18.84 Million | $24.26 Million | +52.61pp |
| 2014-12-31 | 25.06% | $8.25 Million | $32.92 Million | -- |